Experts at HLTH Europe discussed how to ensure patients have trust in the EHDS to ensure a successful roll-out.

Amgen and Zai Lab have reported that the Phase III FORTITUDE-101 trial, assessing bemarituzumab with chemotherapy, achieved ...

BioAtla has presented first-in-human Phase I study data of its anticancer therapy, BA3182, targeting those with metastatic adenocarcinoma.

Assembly Biosciences has dosed the first subject in the Phase Ia/b study’s Phase Ib portion, evaluating ABI-1179.

Novartis’ Cosentyx (secukinumab) has failed to show any benefit in the Phase III study in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the GCAptAIN trial (NCT04930094), ...

Tango has dosed the first subject in the Phase I/II trial of TNG462 with Revolution Medicines' daraxonrasib or zoldonrasib.

INmune Bio said that a subset of Alzheimer's disease patients in the study showed clinical benefit from the therapy.

The trial readout comes at a time of turbulence in the vaccine sector after RFK Jr replaced every member of the ACIP panel.

Pfizer's recent trial termination makes it yet another company facing challenges with CD47 studies in oncology.

The HHS and the FDA have been ordered by US District Judge John Bates to restore the webpages on diversity following the court’s ruling.

GRI Bio has announced encouraging six-week interim safety outcomes from the ongoing Phase IIa trial of GRI-0621.

Belite Bio has completed enrolment in the 24-month PHOENIX Phase III trial assessing the tolerability and safety of oral Tinlarebant.